UK-RNQD-210277. DOP: December 2021.
Hear from dermatology experts across the UK
on the following topics:
 - Andrew Pink.png)
Where are we now in atopic dermatitis (AD)?
Dr Andrew Pink, Consultant Dermatologist at St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust
Clinical overview of RINVOQ: MEASURE UP 1 and 2
Dr Hamish Hunter, Consultant Dermatologist at Salford Royal NHS Foundation Trust
Initiating Therapy
Dr Eirini Merika, Consultant Dermatologist at Chelsea and Westminster Hospital, London
RINVOQ mode of action in AD
Dr Andrew Pink, Consultant Dermatologist at St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust
RINVOQ for treating AD in adolescents
Dr Jen Sharif, Consultant Dermatologist, Salford Royal NHS Foundation Trust
The Impact of AD: Patient Stories
Teena Mackenzie, Biologic, Inflammatory Disease and Research CNS at Royal Berkshire Hospital and Oxford University Hospitals NHS Trust
1. RINVOQ Summary of Product Characteristics
UK-RNQD-210309. Date of preparation: March 2022
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
